Paul Song

Chief Scientific Officer Genequantum Healthcare

As CSO of GQ, I lead a multidisciplinary R&D organization spanning biology, antibody engineering, medicinal chemistry, translational sciences, toxicology, and PK/PD. I have helped shape the company’s scientific vision, R&D strategy, and portfolio, building a differentiated pipeline of next-generation ADCs targeting significant unmet medical needs. During my tenure, we have built a world-class ADC R&D organization and advanced multiple ADC programs into clinical and IND-stage development. Beyond R&D, I work closely with global pharma partners and investors on BD, strategic collaborations, fundraising, and corporate growth.

Seminars

Tuesday 9th March 2027
GQ1035: A First-in-Class Dual Payload ADC with Promising Preclinical Activity in Gastric Cancer
2:45 pm
  • Addressing unmet therapeutic needs in gastric cancer through a novel dual payload ADC strategy
  • Demonstrating promising anti-tumour activity across multiple patient-derived xenograft (PDX) models of gastric cancer
  • Translating preclinical efficacy and emerging biomarker insights into indication selection and future clinical development
Paul Song - GeneQuantum Healthcare